Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 17/20 | 1.00 |
| ▸ | FNTB | P49356 | 17/20 | 1.00 |
| ▸ | PGGT1B | P53609 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683559 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL3552462 | 0.95 | FNTA (0.91) | FNTAFNTBPGGT1BCYP3A4 | |
| Water SCHEMBL3974460 | 0.94 | FNTA (0.89) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL5022612 | 0.90 | FNTA (0.82) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL14588534 | 0.89 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL1683566 | 0.88 | FNTA (0.79) | FNTAFNTBPGGT1B | |
| SCHEMBL5023321 | 0.88 | FNTA (0.79) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL5655368 | 0.87 | FNTA (0.78) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL15314005 | 0.87 | FNTA (0.78) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL14588533 | 0.87 | FNTA (0.77) | FNTAFNTBPGGT1BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089412-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-20220143006-A1 | METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3995589-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | Kura Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-110325212-B | Farnesyl transferase inhibitors for use in methods of treating cancer | 库拉肿瘤学公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20220023287-A1 | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION | EIGER BIOPHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11207314-B2 | Methods of treating cancer patients with farnesyltransferase inhibitors | KURA ONCOLOGY, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210381063-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. (US) | 2021-12-09 | — | — | US | disclosed |
| EP-3640345-B9 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | KURA ONCOLOGY INC (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3640345-B1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | KURA ONCOLOGY INC (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11124839-B2 | Methods of treating cancer patients with farnesyltransferase inhibitors | KURA ONCOLOGY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20180193329-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180187266-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180092903-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. | 2018-04-05 | — | — | US | disclosed |
| EP-3277842-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | Kura Oncology, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20170304291-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9707221-B2 | Methods of treating cancer patients with farnesyltransferase inhibitors | KURA ONCOLOGY, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170071931-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. | 2017-03-16 | — | — | US | disclosed |
| WO-2017031101-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170051356-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2016090107-A2 | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION | EIGER BIOPHARMACEUTICALS, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023287-A1 | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION | IFNAR1, CYP3A43, IFNG | FNTA 569/4885FNTB 38/4885PGGT1B 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.